Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonia and has a median survival after diagnosis of 2–5 years. Pirfenidone is the first approved antifibrotic drug for the treatment of IPF. Here we report the functional progress, side effects and survival...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ther Adv Respir Dis
Hlavní autoři: Vietri, Lucia, Cameli, Paolo, Perruzza, Marco, Cekorja, Behar, Bergantini, Laura, d’Alessandro, Miriana, Refini, Rosa Metella, Pieroni, Maria, Fossi, Antonella, Bennett, David, Spalletti, Marco, Mazzei, Maria Antonietta, Sestini, Piersante, Rottoli, Paola, Bargagli, Elena
Médium: Artigo
Jazyk:Inglês
Vydáno: SAGE Publications 2020
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7029533/
https://ncbi.nlm.nih.gov/pubmed/32066332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1753466620906326
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky